Regrese osteolytického loziska u pacienta s mnohocetným myelomem léceného klodronátem po uspesné terapii rezimem s bortezomibem
[Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen]
Jazyk čeština Země Česko Médium print
Typ dokumentu kazuistiky, časopisecké články
PubMed
21717791
- MeSH
- bortezomib MeSH
- dichlormethylendifosfonát terapeutické užití MeSH
- femur diagnostické zobrazování MeSH
- indukce remise MeSH
- inhibitory kostní resorpce terapeutické užití MeSH
- kyseliny boronové aplikace a dávkování MeSH
- lidé MeSH
- mnohočetný myelom komplikace diagnostické zobrazování farmakoterapie patologie MeSH
- osteolýza komplikace diagnostické zobrazování farmakoterapie MeSH
- protinádorové látky aplikace a dávkování MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- pyraziny aplikace a dávkování MeSH
- radiografie MeSH
- recidiva MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- bortezomib MeSH
- dichlormethylendifosfonát MeSH
- inhibitory kostní resorpce MeSH
- kyseliny boronové MeSH
- protinádorové látky MeSH
- pyraziny MeSH
BACKGROUNDS: Osteolytic lesions are a common manifestation of multiple myeloma, though their healing is rare in these patients. Generally, during a complete remission, lesions only stop progressing; radiologically evident recalcification is exceptional. CASE: Herein we report a case of a male patient born in 1941 and diagnosed in 2005 with IgA multiple myeloma presenting with multiple osteolytic bone lesions. Administration of 4 cycles of VAD chemotherapy (vincristine, adriamycin, dexamethasone) with subsequent autologous peripheral blood stem cell transplantation and maintenance treatment with interferon alpha had resulted into a very good partial remission. In 2009, the disease relapsed with enlargement of osteolytic lesions evident on skiagrams. The largest lesion, reaching 24 x 10 mm in size, was located in the left femur. A complete remission of the disease was achieved with CVD senior regimen (cyclophosphamide, bortezomib, dexamethasone, 8 cycles in total). Bisphosphonates (zoledronate, ibandronate and, from 2007, clodronate) were administered as a long-term supportive therapy. A one-year follow-up skiagram of the left femur revealed over 50% regression of the osteolytic lesion (10 x 5 mm) documented in a set of pictures herein. CONCLUSION: A complete remission of the disease after an administration of bortezomib (Velcade)-based regimen in a long-term clodronate (Bonefos)-treated patient with relapsed multiple myeloma is radiographically apparent by clear healing signs of the osteolytic bone lesion.